News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market

October 29, 2019

On October 16, 2019, PledPharma AB (publ) announced that Nasdaq Stockholm’s Listing Committee approved admission of the company’s shares for trading on Nasdaq Stockholm’s regulated market. The prospectus, prepared in connection with the list change, has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on PledPharma's website,

First day of trading on Nasdaq Stockholm’s main market is scheduled for October 31, 2019 and the last day of trading on Nasdaq First North Growth Market is scheduled for October 30, 2019. The shares will be traded under the same ticker (PLED) and ISIN-code (SE0003815604). There is no fund raising or new share issue in connection with the list change, and shareholders in PledPharma do not need to take any actions.

Pareto Securities AB and Advokatfirman Lindahl KB are PledPharma’s financial and legal advisers respectively, in connection with the listing.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10